![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 37, 26572-26578, September 10, 1999
From the The RNase III family of endoribonucleases
participates in maturation and decay of cellular and viral transcripts
by processing of double-stranded RNA. RNase III degradation is inherent
to most antisense RNA-regulated gene systems in Escherichia
coli. In the hok/sok system from plasmid R1, Sok
antisense RNA targets the hok mRNA for RNase
III-mediated degradation. An intermediate in the pairing reaction
between Sok RNA and hok mRNA forms a three-way junction. A complex between a chimeric antisense RNA and
hok mRNA that mimics the three-way junction was cleaved
by RNase III both in vivo and in vitro.
Footprinting using E117A RNase III binding to partially complementary
RNAs showed protection of the 13 base pairs of interstrand duplex and
of the bottom part of the transcriptional terminator hairpin of the
antisense RNA. This suggests that the 13 base pairs of RNA duplex are
coaxially stacked on the antisense RNA terminator stem-loop and that
each stem forms a monomer half-site, allowing symmetrical binding of
the RNase III dimer. This processing scheme shows an unanticipated
diversity in RNase III substrates and may have a more general
implication for RNA metabolism.
RNase III of Escherichia coli (1) belongs to a family
of double strand-specific endoribonucleases (2, 3), which have retained
interspecies substrate cleavage specificity (4). This family of enzymes
comprises both prokaryotic and eukaryotic members whose primary
function is processing of ribosomal RNA precursors (4-6). However,
substrates also include several mRNAs from E. coli,
bacteriophages Complete or partial duplexes of Here, we have compared the effect of Sok RNA and CA-RNA on
hok mRNA metabolism in rnc+ and
rnc Materials--
Uniformly labeled RNAs
([ Construction of Plasmids--
The
hok
The pTF322 to pTF324 plasmid series was constructed by polymerase chain
reaction-generated fragments inserted into the
EcoRI-BamHI restriction sites of pBR322 using the
following primers: pTF322: T7-1
(5'-CGGGATCCTGTAATACGACTCACTATAGGGCGCTTGAGGCTTTCTGCCTCATG-3') and Hok5 (5'-CCCCGAATTCACAACATCAGCAAGGAGAAA-3') on a pPR633 template carrying a wild-type hok/sok system; pTF323: Hok5 and T7-AN1
(5'-CGGGATCCTGTAATACGACTCACTATAGGGCGCTTGAGGCTGTATGCCGAAAG-3') on a
pTT33 template carrying a pnd-hok hybrid
system2; and pTF324: T7-AN1 and Pnd611
(5'-CCCCGAATTCGCAAAGGCATTCGGCTGGAG-3') using pAN2 carrying a wild-type
pnd system from plasmid R483.
Northern Transfer Analysis--
Northern analysis was carried
out as described (26) using the W3110 (rnc+) and
HT115 (rnc Lead(II) Acetate Probing--
5'-End-labeled CA-RNA or
hok38 RNA was incubated either alone or in complex with an
excess (1 pmol) of partner RNA in a buffer (50 mM Hepes-KOH
(pH 7.5), 10 mM MgCl2, and 50 mM
KCl) supplemented with 5 µg of tRNA in a total reaction volume of 10 µl. Lead(II) acetate (2.5 µl) dissolved in H2O
immediately prior to use was added to a final concentration of 0, 5, or
10 mM and incubated for 5 min at room temperature.
Reactions were quenched by addition of EDTA to a final concentration of
40 mM. The RNA was precipitated, washed twice, resuspended
in formamide dye, and subsequently resolved on 15% polyacrylamide gels
containing 7 M urea and 1× Tris borate/EDTA.
RNA Cleavage Assay--
5 nM RNA was incubated in
the presence or absence of an 10-fold excess of various complementary
partner RNAs in 1× TMK-glutamate buffer (20 mM Tris
acetate, 10 mM magnesium acetate, and 200 mM potassium glutamate) supplemented with 1 mM dithiothreitol
and 1 µg of tRNA in a reaction volume of 20 µl. 50 nM
N-terminal His6-tagged RNase III was added, and samples
were withdrawn to formamide dye on ice at the time points indicated and
subsequently loaded on 5.5 or 15% polyacrylamide gels containing 7 M urea and 0.5× Tris borate/EDTA.
Protein Purification--
RNase III and E117A RNase III, both
carrying N-terminal His6 tags, were purified from strains
W3110 and HT115, respectively, as described (33) with the following
exceptions. A gene encoding wild-type N-terminal
His6-tagged RNase III was cloned in the
EcoRI-BamHI sites of pUHE24-2 (obtained from
Herman Bujard, University of Heidelberg) by polymerase chain reaction
using primers rnc-histagN (5'-CCCTTGAATTCATTAAAGAGGAGAAATTAACTATGCATCACCATCACCATCACAACCCCATCGTAATTAATCGGCTTCAACGG-3') and rnc-BamHI
(5'-CCCTTTGGATCCCGATGCTCATTCCAGCTCCAGTTTTTTC-3'), resulting in pTF600.
The E117A amino acid substitution was introduced by double polymerase
chain reaction using the above primers and rnc-E117A-1 (5'-CCGACACCGTCGCAGCATTAATTGG-3') and rnc-E117A-2
(5'-CCAATTAATGCTGCGACGGTGTCGG-3'), generating pTF601. LacI was
expressed from the co-resident plasmid pMS421, which carries
lacIq and a gene conferring spectinomycin
resistance (34). Initial affinity purification was accomplished by
protein binding to TALONTM resin in 1× binding buffer (4%
(NH4)2SO4 and 30 mM
Tris-HCl (pH 8.0)). Three wash steps in 1× binding buffer were
followed by a wash in 1× binding buffer supplemented with 5 mM imidazole as recommended by the manufacturer
(CLONTECH). Proteins were eluted in 1 M
NH4Cl with 150 mM imidazole and loaded directly
onto a pre-equilibrated poly(I)·poly(C) AG column (Amersham Pharmacia Biotech) as described (33). Eluted protein was dialyzed against 1×
TMK-glutamate buffer supplemented with 1 mM dithiothreitol.
E117A RNase III Footprinting--
One nM
5'-32P-labeled CA-RNA alone or in complex with 10 nM 3H-labeled hok13 was incubated
with 0, 1, or 2.5 µM E117A RNase III in 1× TMK-glutamate
buffer supplemented with 1 mM dithiothreitol and 5 µg of
tRNA in a 20-µl reaction volume at room temperature. 0.1 unit of
cobra venom nuclease (Amersham Pharmacia Biotech) was added for 5 min,
and reactions were quenched by addition of 80 µl of phenol. RNA
samples were precipitated, washed, resuspended in formamide dye, and
resolved on a 15% polyacrylamide gel containing 7 M urea
and 0.5× Tris borate/EDTA.
Cleavage Kinetics and Substrate Affinity
Determinations--
Km and
kcat calculations were made by a
double-reciprocal plot of 1/V (initial velocity)
versus 1/S (substrate concentration) as described (33). 7.5 nM N-terminal His6-tagged RNase III dimer was
incubated with 62-1000 nM preformed complexes between
32P-labeled antisense RNA and equimolar
3H-labeled target RNA in a 10-µl reaction volume using
TMK-glutamate buffer supplemented with 1 mM dithiothreitol
(see above). Samples were quenched after 2 min by addition of formamide
dye loading buffer. RNAs were resolved on a 15% polyacrylamide gel
containing 7 M urea and 0.5× Tris borate/EDTA.
In Vivo RNase III Processing of hok mRNA--
To test the
effect of natural and artificial antisense RNAs on the level of
hok mRNA in vivo, a hok/sok system
with abolished Sok RNA expression was constructed and cloned into a
low-copy number mini-R1 plasmid (pTF821). To avoid detrimental
expression of the Hok toxin, this construct carries an amber stop codon
mutation in the hok gene (hok
Plasmid pTF820 is the isogenic sok+ derivative
of pTF821 that produces wild-type Sok RNA in cis. Wild-type
cells carrying pTF820 do not contain detectable amounts of the
3'-truncated mRNA due to its rapid interaction with Sok RNA and
subsequent rapid cleavage by RNase III (Fig. 2, left panel,
lane 1) (26). Consistent with this interpretation, the
truncated RNA appears in cells devoid of RNase III (Fig. 2, right
panel, lane 1).
We examined the effect of three antisense RNAs expressed in
trans from pBR322-derived plasmids on the hok
mRNA band pattern in rnc+ and
rnc
When we examined the hok mRNA in an
rnc The CA-RNA·hok mRNA Complex Forms a Three-way Junction in
Vitro--
hok38 RNA constitutes the antisense target
stem-loop structure in hok mRNA shown schematically in
Fig. 1D. We tested the in vitro complex formed
between CA-RNA and hok38 RNA by lead(II) acetate probing of
5'-end-labeled CA-RNA (Fig.
3A, left panel) or
hok38 (Fig. 3A, right panel) either
alone or in complex with hok38 or CA-RNA, respectively. The
interpretation of the RNA probing is shown in Fig. 3B.
Single strand-specific lead(II) acetate cleavages were observed in the
5'-tail and in the top stem and loop region of the unpaired CA-RNA.
Binding of hok38 to 32P-labeled CA-RNA resulted
in repression of cleavages at the tail nucleotides only, whereas
cleavages at other sites were unaffected (Fig. 3A,
left panel). Probing of unpaired hok38 resulted
in cleavages in the loop and in the top stem region (Fig.
3A, right panel). Binding of CA-RNA specifically
protected the nucleotides that are complementary to the bases in the
tail of CA-RNA. Although binding of CA-RNA caused a modest enhancement
of cleavages in the bottom stem of hok38 (Fig.
3A, right part of the left panel), the
probing supports the formation of the three-way junction, as shown in
Fig. 3B.
In Vitro RNase III Processing of the TWJ--
Different antisense
RNA/target RNA combinations were tested for their ability to function
as RNase III-processing signals in vitro using purified
histidine-tagged RNase III (Fig. 4). The cleavage reactions were performed at high stringency (i.e.
at a high concentration of monovalent salt). As expected, truncated hok mRNA alone was not affected by RNase III (Fig.
4A, left panel), consistent with the
extraordinary stability of this mRNA in vivo (28).
Addition of Sok RNA resulted in a major cleavage product in addition to
multiple consecutive cleavage fragments (MCF; Fig. 4A, middle panel). In contrast, addition of
CA-RNA to truncated hok mRNA yielded two well defined
cleavage products, indicative of a single specific cleavage site.
Consistently, the longest cleavage fragments in the two reactions were
of similar sizes (Fig. 4A).
We also examined RNase III cleavage of labeled wild-type Sok RNA (Fig.
4B) and CA-RNA (Fig. 4C). Alone, both RNAs were
resistant to RNase III processing. The lack of cleavage is consistent
with the presence of upper stem helix irregularities that may act to protect the RNAs from RNase III cleavage. Such stem irregularities are
known to prevent RNase III cleavage (35). Addition of truncated hok mRNA resulted in multiple cleavages of Sok RNA (Fig.
4B, middle panel) and a single cleavage of CA-RNA
(Fig. 4C, middle panel), consistent with the
cleavage pattern observed for hok mRNA in Fig.
4A. These results show that all RNase III cleavages
described here reflect coordinated double-strand scissions.
Furthermore, primer-extension analysis showed that all double-strand
cleavages occurred at the phosphodiester bond between nucleotides +13
and +14 of the antisense 5'-tail and the corresponding phosphodiester bond in hok mRNA, resulting in a 2-nucleotide
3'-overhang according to consensus RNase III processing (data not
shown). This cleavage site is designated position 13/11 below.
As implied by the in vivo and in vitro RNase III
processing experiments, a partial duplex between the CA-RNA antisense
RNA and the hok mRNA seems to be sufficient for RNase
III processing. A 14-nucleotide fragment (hok13) of
hok mRNA sequence that is complementary to the
13-nucleotide 5'-tail of Sok RNA and CA-RNA was synthesized (the
fragment carried an additional 5'-G for efficient transcription by T7
RNA polymerase). Addition of hok13 to Sok RNA or CA-RNA
resulted in single specific RNase III cleavages (Fig. 4, B
and C, right panels) at the same processing site
at position 13/11 described above (data not shown). These observations are consistent with the in vivo processing data and confirm
that a partial antisense RNA/target RNA duplex comprising 13 bp of interstrand pairing is adequate for RNase III processing.
To test if all 13 bp of the duplex were required for processing, we
examined 3'-end-shortened hok mRNA fragments of 7 (hok7) and 10 (hok10) nucleotides for RNase
III-mediated CA-RNA cleavage (Fig. 4D). hok7
failed to sustain cleavage (Fig. 4D, left panel), whereas partial cleavage was observed with hok10
(middle panel). Thus, all 13 base pairs are required for
optimal enzyme binding or processing. In addition, the cleavage
observed with hok10 occurred at the site at position 13/11
described above, implying that binding and/or cleavage is fixed at a
unique position and does not change with the 5'-end border of the
partial duplex (data not shown).
Cleavage Kinetics and Substrate Affinity--
The kinetic
parameters for RNase III processing of Sok RNA in duplex with
hok13 and CA-RNA in duplexes with hok13 and
hok38 are shown in Table I.
The kcat and Km values for
RNase III processing of all three complexes are similar to the values calculated for the R1.1 substrate from bacteriophage T7 using wild-type
RNase III (33). In addition, the formation of a TWJ in the
CA-RNA·hok38 complex does not impair affinity or cleavage rate compared with the Sok RNA·hok13 and
CA-RNA·hok13 complexes. Thus, the in vitro
kinetic parameters for RNase III processing of the partial duplexes
clearly support the ability of this substrate to compete for
RNase III binding and cleavage in vivo.
The Transcriptional Terminator Stem-Loop Structure Is Prerequisite
for RNase III Cleavage of hok13--
Complexes formed between
uniformly 32P-labeled hok13 and Sok RNA, CA-RNA,
or Sok13, which corresponds to the 13 nucleotides of the 5'-tail
sequence of Sok RNA (and CA-RNA) were examined for accurate RNase III
cleavage (Fig. 5). Binding of either Sok RNA or CA-RNA resulted in RNase III cleavage at the specific site in
hok13. In contrast, RNase III failed to perform accurate
processing of the hok13·Sok13 complex. Hence, the 13 base
pair interstrand RNA duplex is not a substrate for RNase III. These
results show that the transcriptional terminator hairpins of Sok RNA
and CA-RNA are necessary for RNase III processing. The cleavage sites
at position 13/11 suggest that the 13 bp of antisense RNA/target RNA
duplexes and the bottom stem of the antisense RNA transcriptional terminator hairpins each constitute RNase III monomer half-sites.
RNase III Binding to Coaxially Stacked RNA Helices--
RNase III
binding was examined using an RNase III derivative carrying an E117A
amino acid substitution. This protein shows binding properties
identical to those of the wild-type enzyme, but is impaired in
substrate cleavage (13). 32P-5'-End-labeled CA-RNA was
incubated either alone or with hok13 in the presence or
absence of E117A RNase III (Fig.
6A). As the substrates tested
contained almost exclusively double-stranded or stacked nucleotides, we
used cobra venom nuclease to monitor substrate binding (Fig.
6B). At both concentrations of E117A RNase III, the unpaired
CA-RNA was not protected from cobra venom nuclease cleavages. Adding
the hok13 fragment resulted in E117A RNase III-mediated protection of the 5'-tail and bottom hairpin at both the 5'- and 3'-sides. These data are consistent with a symmetrical binding of E117A
RNase III coaxially stacked helices that comprise the bottom part of
the CA-RNA transcriptional terminator hairpin stacked on the 13 bp of
the interstrand CA-RNA/hok13 duplex. A structural model
showing the protection of the CA-RNA·hok13 complex by
E117A RNase III is presented in Fig. 6B. Protection extends
roughly 10-12 bp on each side of the cleavage sites, which are located in the hinge region of the stacked helices (Fig. 6A).
Many antisense RNAs target their complementary transcripts for
RNase III-mediated degradation. Although the antisense RNAs of the Sok
RNA family can form complete duplexes with their target RNAs, our data
show that a pairing intermediate of 13 base pairs that forms a TWJ is
sufficient for RNase III-mediated degradation in vivo.
Intriguingly, substrates corresponding to the transcripts examined
in vivo were cleaved by purified RNase III at a single specific site in both strands of the antisense RNA/target RNA duplexes.
Our data support a minimal substrate that consists of the antisense RNA
transcriptional terminator hairpin and the 13 nucleotides of the
5'-tail engaged in RNA interstrand pairing. However, RNase III
processing normally requires at least two helical turns of RNA duplex
(2, 3). Indeed, the 13 bp of duplex are necessary, yet insufficient for
RNase III cleavage (Fig. 4). E117A RNase III protein footprinting
supports enzyme binding at the 13 bp of interstrand duplex and at the
bottom 10-12 bp of the antisense RNA hairpin stem. This substrate most
likely forms a rigid coaxially stacked structure that constitutes more
than two helical turns of RNA helix, thus being reminiscent of more conventional RNase III substrates. The observation that RNase III is
unable to perform any cleavage on the 13-bp duplex substrate suggests
either of the following. (i) Simultaneous contact between the substrate half-sites and the dsRNA-binding motifs of each
RNase III subunit is required to confer catalytic activity to the
enzyme. This could occur by structural transitions of the enzyme upon
substrate binding, perhaps to attain the transition state.
(ii) Binding of a single monomer subunit to the RNA complex provides insufficient binding energy to sustain substrate cleavage.
Consistent with the above-described conclusions, the footprinting
experiment showed that binding of the dimeric E117A RNase III requires
both monomer half-sites of the CA-RNA·hok13 complex (Fig.
6). The absence of protection of the monomer half-site in CA-RNA
suggests that the equilibrium dissociation constant for the interaction
between the RNase III dsRBD and the half-site is significantly higher
than 2.5 µM. A low binding affinity for such a
monomer/half-site interaction is expected to increase the stringency in
substrate binding and to prevent titration of RNase III by dsRNA
elements that are not RNase III substrates. The Km and kcat values for CA-RNA in partial duplex
with hok13 and hok38 and for Sok RNA in complex
with hok13 are similar to the values previously reported for
RNase III processing (33) and concur with the observation that the
CA-RNA·hok mRNA substrate is efficiently processed
in vivo. Thus, formation of the TWJ in the
CA-RNA·hok mRNA complex (Figs. 1D and 3)
does not impede RNase III processing (Figs. 2 and 4 and Table I), which
could suggest that the enzyme does not form a tightly closed complex
surrounding the cleavage site since the extra RNA stem is accommodated
by the catalytic site without affecting
kcat.
Several RNase III substrates have structural irregularities
(i.e. bulges, mismatches, and internal loops) (2) around the scissile bonds, including the Sok RNA·hok13 and
CA-RNA·hok13 complexes and the R1.1 substrate of
bacteriophage T7. However, data obtained with the native R1.1 substrate
of bacteriophage T7 and an engineered version with perfect helicity
showed similar equilibrium dissociation constants, suggesting that
little or no discrimination on substrate binding is conferred by the
catalytic site (13). Instead, the recent finding of RNase III binding
anti-determinants implies that the stringency of processing is on the
level of enzyme binding exclusively (21). Consistent with the efficient
processing, none of the substrates tested here convey the RNase III
binding anti-determinants. Alignment of RNase III-processing signals
from E. coli has identified a preference for a C-G base pair
at position +6/+4 relative to the scissile bonds (21, 37).
Interestingly, the CA-RNA·hok mRNA complex contains
one C-G base pair in the tail/target duplex and one C-G base pair in
the terminator hairpin of CA-RNA located symmetrically (disregarding
the bulged-out U) at position +6/+4 (Fig. 6B). The crystal
structure of the dsRBD of the dsRNA-binding protein A of X. laevis in complex with dsRNA revealed a single sequence-specific
contact between a backbone carbonyl group and the exocyclic amine of G
in the minor groove of a C-G base pair (20). Thus, a similar
interaction could be important for RNase III binding of its substrates
and may in some cases specify the cleavage site location. This is
supported by the fixed cleavage site at position 13/11 observed here
for RNase III processing of the CA-RNA·hok10 complex, for
which the end of the interstrand duplex has been juxtaposed, compared
with the CA-RNA·hok mRNA and CA-RNA·hok13 complexes.
The fact that the family of RNase III enzymes shows at least partial
interspecies substrate specificity (4) suggests that coaxially stacked
helices could function as processing signals for RNase III enzymes in
both prokaryotic and eukaryotic cells. Recently, an RNase
III-processing signal composed of noncontiguous helices was suggested
for the small nuclear R40 precursor of S. cerevisiae (10).
However, for this substrate, the junction of the RNA helices is
positioned 6-8 base pairs from the scissile phosphodiester bonds, most
likely displaced from the catalytic site.
Intriguingly, binding of coaxially stacked dsRNA by two copies of the
double dsRBD may apply to a diverse set of proteins with unrelated
function. In a recent experiment, the dsRBD of PKR was shown to bind
in vitro selected RNA with noncontiguous and most likely
coaxially stacked RNA helices (38). Thus, it is conceivable that
enzymes like PKR and ADAR (adenine deaminase that acts on RNA) that carry multiple copies of
the dsRBD can bind coaxially stacked RNA stems in a fashion similar to
RNase III and thereby trigger such diverse cellular responses as
apoptosis, the interferon-induced viral response (39, 40), or RNA
degradation (41).
The processing of coaxially stacked RNA helices reported here shows
that RNase III substrates are more versatile than previously assumed.
This novel substrate specificity could have a more general implication
on the metabolism of diverse RNAs.
We thank E. G. H. Wagner for
critical reading of the manuscript.
*
This work was supported by the Center for Interaction,
Structure, Function, and Engineering of Macromolecules of the Danish Biotechnology Program.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel:
45-65-50-24-13; Fax: 45-65-93-27-81.; E-mail:
kgerdes@molbiol.ou.dk.
2
T. Thisted, unpublished data.
The abbreviations used are:
dsRNA, double-stranded RNA;
dsRBD, double-stranded RNA-binding domain;
bp, base pair(s);
CA-RNA, chimeric antisense RNA;
TWJ, three-way
junction.
Ribonuclease III Processing of Coaxially Stacked RNA Helices*
,
¶
Department of Molecular Biology, Odense
University, Campusvej 55, DK-5230 Odense M, Denmark and the
§ Howard Hughes Medical Institute, Department of Genetics,
University of Pennsylvania School of Medicine, Philadelphia,
Pennsylvania 19104
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and T7 (2, 3), U5 small nuclear RNA (7), U2 small
nuclear RNA (8), and a large subset of small nucleolar RNA precursors
of Saccharomyces cerevisiae (9, 10). Substrate recognition
requires two helical turns of an A-form RNA helix, and processing
occurs with a consensus 2-nucleotide, 3'-recessive, staggered cut
creating 5'-phosphate and 3'-hydroxyl termini (11, 12). The E. coli RNase III holoenzyme is a homodimer of 52 kDa that binds
dsRNA1 in a quasi-symmetrical
fashion concentrical of the scissile phosphodiester bonds (13). RNase
III binding is dependent on a conserved dsRNA-binding motif present in
the C-terminal end that forms an
-
-
-
-
fold (14). Binding
of dsRNA is believed to occur primarily via non-electrostatic interactions with a helical arrangement of 2'-hydroxyl groups in the
minor groove as described for the dsRNA-binding motif binding of the
mammalian dsRNA-activated protein kinase, PKR (15). In addition, a
lysine residue may be required for dsRNA binding, similar to what has
been observed for the staufen protein from Drosophila (16)
and PKR (17-19). Binding of the dsRBD of RNA-binding protein A from
Xenopus laevis to dsRNA has shown that two regions of the
dsRBD contact successive minor grooves on the same face of the
double-stranded RNA helix, whereas a third region contacts the spanning
major groove (20). However, the recent finding of binding sequence
anti-determinants in dsRNA that abolish RNase III cleavage in
vitro (21) emphasizes the subtleties of substrate recognition by
RNase III and may explain why certain dsRNA sequences like the human
immunodeficiency virus type 1 TAR RNA hairpin are inherently refractory
to processing (4).
20 bp formed between antisense RNAs
and their target RNAs are efficiently processed by RNase III
(22-26). The hok (host cell
killing) mRNA from the hok/sok (suppression of killing) system of
plasmid R1 (27) exists in three forms with alternative configurations
and translational capacities (28). Sok antisense RNA consists of an
11-nucleotide 5'-single-stranded tail that is responsible for the
initial interaction with hok mRNA and a hairpin that
functions as a Rho-independent transcriptional terminator (Fig.
1A). Sok RNA represses
hok translation by forming a 63-bp duplex with
hok mRNA (Fig. 1C). The duplex is cleaved by
RNase III in vivo and in vitro (26). Since
formation of RNA/RNA binding intermediates could be faster than the
formation of a full duplex between Sok RNA and hok mRNA,
inactivation of the target RNA could occur prior to complete duplex
formation, as in the cases of several other antisense RNA-regulated
gene systems (29). To test this, we constructed a chimeric antisense RNA (CA-RNA) consisting of the 13-nucleotide 5'-tail of Sok fused to
the terminator hairpin of PndB, an antisense RNA from plasmid R483 that
is homologous to Sok (Fig. 1B). CA-RNA forms a 13-base pair
duplex with hok mRNA, thereby resulting in the
generation of a three-way junction (Fig. 1D, left
panel). This complex mimics the naturally occurring binding
intermediate between hok mRNA and Sok antisense RNA
(Fig. 1D, right panel). Surprisingly, CA-RNA was
able to inhibit hok expression in
vivo,2 thus questioning
the actual mechanism of hok target inactivation by Sok
RNA.

View larger version (22K):
[in a new window]
Fig. 1.
Primary and secondary structures of antisense
RNAs and deduced RNA complexes. A and B,
primary and secondary structures of Sok and chimeric antisense RNAs,
respectively. Sok RNA sequence is shown in boldface, and the
sequence from the Sok homologous PndB antisense RNA is shown in
lightface. C, complete duplex formation (63 bp)
between Sok RNA and hok mRNA. Initial RNase III cleavage
sites at position 13/11 examined throughout this study are indicated.
D, schematic comparison of the complex formed between CA-RNA
and hok mRNA (left panel) with the metastable
Sok RNA/hok mRNA pairing intermediate (right
panel). CA-RNA (B) can only form a 13-base pair partial
duplex with the hok mRNA and thus mimics the naturally
occurring transient TWJ complex. hok/sok sequence is shown
with boldface lines, and pnd sequence with
lightface lines. The part of hok mRNA shown
in D consists of the 38 nucleotides (nt) that
form the antisense RNA target stem-loop. Arrows indicate the
RNase III cleavage sites at position 13/11 in the
hok/sok duplex examined throughout this
study.
strains. Complexes between antisense and
target RNAs that correspond to the RNA complexes observed in
vivo were assayed for RNase III binding and processing in
vitro. Intriguingly, all data support a model in which RNase III
recognizes and cleaves coaxially stacked RNA helices.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]CTP or [
-3H]CTP) were
synthesized using T7 RNA polymerase (Promega) and polymerase chain
reaction-generated templates (30). 5'-32P-Labeled RNAs were
prepared with alkaline phosphatase (Roche Molecular Biochemicals), T4
kinase (Roche Molecular Biochemicals), and [
-32P]ATP
using standard techniques (31). RNAs were purified as described
(30).
/sok+ and
hok
/sok
constructs
described previously (32) were inserted in the
BamHI-EcoRI restriction sites of the low-copy number mini-R1 test plasmid pMH82 (KanR). Thus,
pTF821(hok
/sok+)
carries a hok/sok system with an amber codon in
the hok gene, whereas
pTF821(hok
/sok
)
carries an additional point mutation that inactivates the
sok promoter. These mutations do not influence the stability
or processing patterns of hok mRNA (30).
) E. coli strains grown
in LB broth supplemented with 50 µg/ml kanamycin and 100 µg/ml
ampicillin for retainment of the mini-R1 test plasmid and pBR322
antisense RNA-donating plasmid, respectively. 10 µg/ml tetracycline
was added to the HT115 strain.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
).
Northern analysis showed that wild-type E. coli cells
(strain W3110, rnc+) carrying pTF821 contain
three hok mRNA species (Fig.
2, left panel, lane
2). We have shown previously that hok mRNA-1 and -2 are full-length mRNAs that are translationally inactive and bind Sok RNA inefficiently, whereas the third RNA is a 3'-truncated species
(denoted Tr. in Fig. 2) that is translationally active and
binds Sok RNA avidly (28). hok mRNA-2 is an RNase III
cleavage product of RNA-1 (Fig. 2, compare left and
right panels). This latter cleavage removes the 3'-terminal
hairpin of RNA-1 and does not influence the analyses presented here
(26).

View larger version (34K):
[in a new window]
Fig. 2.
Northern transfer analysis of hok mRNAs. Shown are the results from Northern transfer
analysis of hok mRNAs in W3110
(rnc+; left panel) and HT115
(rnc
; right panel). The
hok mRNAs were expressed from a mini-R1 plasmid carrying
either hok
/sok+
(pTF820) (lane 1) or
hok
/sok
(pTF821)
(lanes 2-6) gene systems. The hok
and sok
genotypes denote an amber mutation in
the hok gene preventing toxin expression and a mutation in
the sok promoter that abolishes Sok RNA expression,
respectively (32). Lane 3, the pBR322 control plasmid;
lanes 4-6, wild-type Sok RNA (pTF322) and CA-RNA (pTF323)
and PndB (pTF324) antisense RNAs produced in trans from
pBR322-derived plasmids, respectively. Translationally inactive
hok mRNA-1 and -2 as well as the active truncated
(Tr.) hok mRNA are indicated. hok
mRNA-2 is not produced in the rnc
strain.
cells (Fig. 2). The pBR322 control plasmid
did not affect the hok mRNA band pattern (Fig. 2,
left panel, lane 3). In trans
expression of wild-type Sok RNA from pTF322 resulted in the
disappearance of the truncated mRNA (Fig. 2, left panel,
lane 4). The high level of Sok RNA production also resulted
in a modest reduction in hok mRNA-1 and -2, presumably
due to antisense RNA binding to hok mRNA during its
synthesis (Fig. 2, left panel, lane 4).
Interestingly, expression of CA-RNA also caused the disappearance of
truncated hok mRNA (Fig. 2, left panel,
lane 5), an effect similar to that of Sok RNA. In contrast,
wild-type PndB antisense RNA (pTF324) from plasmid R483 had no effect
on hok mRNA (Fig. 2, left panel, lane
6).
strain, neither Sok RNA nor CA-RNA
affected the metabolism of truncated hok mRNA (Fig. 2,
right panel). Thus, CA-RNA, which carries 13 nucleotides
that are complementary to hok mRNA, is sufficient to
target the truncated hok mRNA for degradation in the
rnc+ strain. These results indicate that CA-RNA
and the truncated hok mRNA form a partial duplex
(i.e. the TWJ; see below) that is adequate for RNase
III-mediated hydrolysis in vivo.

View larger version (39K):
[in a new window]
Fig. 3.
Demonstration that CA-RNA and the minimal
target RNA form at the three-way junction. Shown are the results
from lead(II) acetate probing of the complex formed between CA-RNA and
hok38 RNA. A, 50 fmol of
32P-5'-end-labeled CA-RNA (left panel) or
hok 38 (right panel) was incubated either alone
or in complex with an excess (1 pmol) of unlabeled hok38 or
CA-RNA, respectively. Lead(II) acetate was added at the concentrations
indicated. RNase T1 cleavage reactions (T1) were carried out
as (36) on native RNA. L denotes the alkaline ladders. The
loops of CA-RNA and hok38 and the single-stranded 5'-tail of
CA-RNA are indicated. The bulged-out A33 of
hok38 is indicated to aid cleavage site localization.
B, shown is the structure of the complex formed between
CA-RNA and hok38 based on the lead(II) acetate probing
results in A. The 13 nucleotides of the 5'-tail of CA-RNA
that are complementary to the target in hok38 are shown in
boldface, and the RNA stem-loop structure derived from the
PndB antisense RNA in lightface. Lead(II) acetate cleavages
of labeled CA-RNA and hok38 that are unaffected by complex
formation are indicated by asterisks, whereas cleavage sites
repressed upon complex formation are indicated by boldface
lines. RNase T1 cleavage sites are indicated with thin
arrows.

View larger version (55K):
[in a new window]
Fig. 4.
In vitro RNase III processing of
the three-way junction and of coaxially stacked RNA helices.
Uniformly 32P-labeled hok mRNA
(A), Sok RNA (B), and CA-RNA (C and
D) were preincubated either alone or with a 10-fold excess
of 3H-labeled partner RNA as indicated for 30 min before
addition of N-terminal His6-tagged RNase III at 37 °C
(A-C) or 25 °C (D). Samples were withdrawn at
the time points indicated. Uncleaved RNA (UC), the 5'- and
3'-end cleavage products, and the multiple cleavage fragments
(MCF) resulting from consecutive RNase III processings are
indicated by arrowheads.
Kinetic parameters for RNase III processing of minimal RNA substrates

View larger version (60K):
[in a new window]
Fig. 5.
In vitro RNase III cleavage of
uniformly 32P-labeled hok13 transcripts. The assays were conducted as described in the
legend to Fig. 3 at 37 °C. The alkali ladder (L) was made
on a 32P-5'-end-labeled hok13 fragment as
described (36). Uncleaved RNA (UC) and the 5'- and
3'-cleavage products corresponding to 3 and 11 nucleotides,
respectively, are indicated.

View larger version (49K):
[in a new window]
Fig. 6.
Footprinting of E117A RNase III on a minimal
CA-RNA·hok13 complex. A,
footprinting of E117A RNase III on 32P-5'-end-labeled
CA-RNA using cobra venom nuclease to monitor protein/RNA interaction.
50 fmol of 32P-labeled CA-RNA was preincubated either alone
(lanes 1-4) or with a 10-fold excess of
3H-labeled hok13 (lanes 5-8). E117A
RNase III was added to a final concentration of 0 µM
(lanes 1 and 5), 1 µM (lanes
2 and 6), or 2.5 µM (lanes 3 and 7) and probed with cobra venom ribonuclease (lanes
1-3 and 5-7). The product(s) of cleavage reactions
using wild-type RNase III (lanes 4 and 8) are
shown by an arrowhead. RNase T1 cleavage (T1) on
native RNA and the alkali ladder (L) were as described (36).
C indicates the control reaction in which E117A RNase III
and cobra venom nuclease were omitted. B, the secondary
structure and coaxially stacked helices of the
CA-RNA·hok13 complex. The hok/sok sequence is
shown in boldface, and the PndB sequence in
lightface. The approximate extent of E117A RNase III
protection from A is shown with boldface lines. The proposed symmetrical binding of RNase III on each
half-site is illustrated by double barrels, and the
positions of the staggered dsRNA breaks are indicated by
arrows. The symmetrically located C-G base pairs described
under "Discussion" are boxed.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Robertson, H. D.,
Webster, R. E.,
and Zinder, N. D.
(1968)
J. Biol. Chem.
243,
82-91 2.
Court, D.
(1993)
in
Control of Messenger RNA Stability
(Belasco, J. G.
, and Brawerman, G., eds)
, pp. 71-116, Academic Press, Inc., San Diego, CA
3.
Nicholson, A. W.
(1996)
Prog. Nucleic Acid Res. Mol. Biol.
52,
1-65[Medline]
[Order article via Infotrieve]
4.
Rotondo, G.,
Huang, J. Y.,
and Frendewey, D.
(1997)
RNA
3,
1182-1193[Abstract]
5.
Young, R. A.,
and Steitz, J. A.
(1978)
Proc. Natl. Acad. Sci. U. S. A.
75,
3593-3597 6.
Abou-Elela, S.,
Igel, H.,
and Ares, M.
(1996)
Cell
85,
115-124[CrossRef][Medline]
[Order article via Infotrieve]
7.
Chanfreau, G.,
Abou Elela, S.,
Ares, M., Jr.,
and Guthrie, C.
(1997)
Genes Dev.
11,
2741-2751 8.
Abou Elela, S.,
and Ares, M., Jr.
(1998)
EMBO J.
17,
3738-3746[CrossRef][Medline]
[Order article via Infotrieve]
9.
Chanfreau, G.,
Rotondo, G.,
Legrain, P.,
and Jacquier, A.
(1998)
EMBO J.
17,
3726-3737[CrossRef][Medline]
[Order article via Infotrieve]
10.
Chanfreau, G.,
Legrain, P.,
and Jacquier, A.
(1998)
J. Mol. Biol.
284,
975-988[CrossRef][Medline]
[Order article via Infotrieve]
11.
Dunn, J. J.
(1982)
in
The Enzymes
(Boyer, P. D., ed), Vol. 15, Part B
, pp. 485-499, Academic Press, New York
12.
Robertson, H. D.
(1982)
Cell
30,
669-672[CrossRef][Medline]
[Order article via Infotrieve]
13.
Li, H.,
and Nicholson, A. W.
(1996)
EMBO J.
15,
1421-1433[Medline]
[Order article via Infotrieve]
14.
Kharrat, A.,
Macias, M. J.,
Gibson, T. J.,
Nilges, M.,
and Pastore, A.
(1995)
EMBO J.
14,
3572-3584[Medline]
[Order article via Infotrieve]
15.
Bevilacqua, P. C.,
and Cech, T. R.
(1996)
Biochemistry
33,
9983-9994
16.
Bycroft, M.,
Grünert, S.,
Murzin, A. G.,
Proctor, M.,
and Johnston, D.
(1995)
EMBO J.
14,
3563-3571[Medline]
[Order article via Infotrieve]
17.
Green, S. R.,
and Mathews, M. B.
(1992)
Genes Dev.
6,
2478-2490 18.
Green, S. R.,
Manche, L.,
and Mathews, M. B.
(1995)
Mol. Cell. Biol.
15,
358-364[Abstract]
19.
McMillan, N. A. J.,
Carpick, B. W.,
Hollis, B.,
Toone, W. M.,
Zamanian-Daryoush, M.,
and Williams, B. R. G.
(1995)
J. Biol. Chem.
270,
2601-2606 20.
Ryter, J. M.,
and Schultz, S. C.
(1998)
EMBO J.
17,
7505-7513[CrossRef][Medline]
[Order article via Infotrieve]
21.
Zhang, K.,
and Nicholson, A. W.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13437-13441 22.
Krinke, L.,
and Wulff, D. L.
(1987)
Genes Dev.
1,
1005-1013 23.
Case, C. C.,
Simons, E. L.,
and Simons, R. W.
(1990)
EMBO J.
9,
1259-1266[Medline]
[Order article via Infotrieve]
24.
Blomberg, P.,
Wagner, E. G. H.,
and Nordström, K.
(1990)
EMBO J.
9,
2331-2340[Medline]
[Order article via Infotrieve]
25.
Malmgren, C.,
Wagner, E. G. H.,
Ehresmann, C.,
Ehresmann, B.,
and Romby, P.
(1997)
J. Biol. Chem.
272,
12508-12512 26.
Gerdes, K.,
Nielsen, A. K.,
Thorsted, P.,
and Wagner, E. G. H.
(1992)
J. Mol. Biol.
226,
637-649[CrossRef][Medline]
[Order article via Infotrieve]
27.
Gerdes, K.,
Gultyaev, A. P.,
Franch, T.,
Pedersen, K.,
and Mikkelsen, N. D.
(1997)
Annu. Rev. Genet.
31,
1-31[CrossRef][Medline]
[Order article via Infotrieve]
28.
Franch, T.,
Gultyaev, A. P.,
and Gerdes, K.
(1997)
J. Mol. Biol.
273,
38-51[CrossRef][Medline]
[Order article via Infotrieve]
29.
Brantl, S.,
and Wagner, E. G. H.
(1998)
Trends Biochem. Sci.
23,
451-454[CrossRef][Medline]
[Order article via Infotrieve]
30.
Thisted, T.,
Sørensen, N. S.,
Wagner, E. G. H.,
and Gerdes, K.
(1994)
EMBO J.
13,
1960-1968[Medline]
[Order article via Infotrieve]
31.
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring, NY
32.
Thisted, T.,
and Gerdes, K.
(1992)
J. Mol. Biol.
223,
41-54[CrossRef][Medline]
[Order article via Infotrieve]
33.
Li, H.,
Chelladurai, B. S.,
Zhang, K.,
and Nicholson, A. W.
(1993)
Nucleic Acids Res.
21,
1919-1925 34.
Graña, D. T.,
Gardella, T.,
and Susskind, M. M.
(1988)
Genetics
120,
319-327 35.
Hjalt, T. Å. H.,
and Wagner, E. G. H.
(1995)
Nucleic Acids Res.
23,
571-579 36.
Thisted, T.,
Sørensen, N. S.,
and Gerdes, K.
(1995)
J. Mol. Biol.
247,
859-873[CrossRef][Medline]
[Order article via Infotrieve]
37.
Krinke, L.,
and Wulff, D. L.
(1990)
Nucleic Acids Res.
18,
4809-4815 38.
Bevilacqua, P. C.,
George, C. X.,
Samuel, C. E.,
and Cech, T. R.
(1998)
Biochemistry
37,
6303-6316[CrossRef][Medline]
[Order article via Infotrieve]
39.
Der, S. D.,
Yang, Y.-L.,
Weissmann, C.,
and Williams, B. R. G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3279-3283 40.
Wong, A. H.-T.,
Tam, N. W. N.,
Yang, Y.-L.,
Cuddihy, A. R.,
Li, S.,
Kirchhoff, S.,
Hauser, H.,
Decker, T.,
and Koromilas, A. E.
(1997)
EMBO J.
16,
1291-1304[CrossRef][Medline]
[Order article via Infotrieve]
41.
Scadden, A. D. J.,
and Smith, C. W. J.
(1997)
EMBO J.
16,
2140-2149[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. H. Urban and J. Vogel Translational control and target recognition by Escherichia coli small RNAs in vivo Nucleic Acids Res., February 16, 2007; 35(3): 1018 - 1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. R. Faridani, A. Nikravesh, D. P. Pandey, K. Gerdes, and L. Good Competitive inhibition of natural antisense Sok-RNA interactions activates Hok-mediated cell killing in Escherichia coli Nucleic Acids Res., November 6, 2006; 34(20): 5915 - 5922. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Pertzev and A. W. Nicholson Characterization of RNA sequence determinants and antideterminants of processing reactivity for a minimal substrate of Escherichia coli ribonuclease III Nucleic Acids Res., August 8, 2006; 34(13): 3708 - 3721. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zer and G. Chanfreau Regulation and Surveillance of Normal and 3'-Extended Forms of the Yeast Aci-reductone Dioxygenase mRNA by RNase III Cleavage and Exonucleolytic Degradation J. Biol. Chem., August 12, 2005; 280(32): 28997 - 29003. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gottesman Stealth regulation: biological circuits with small RNA switches Genes & Dev., November 15, 2002; 16(22): 2829 - 2842. [Full Text] [PDF] |
||||
![]() |
T. Moller, T. Franch, C. Udesen, K. Gerdes, and P. Valentin-Hansen Spot 42 RNA mediates discoordinate expression of the E. coli galactose operon Genes & Dev., July 1, 2002; 16(13): 1696 - 1706. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Y. Wu, J.-F. Fu, and S.-T. Liu The replicon of pSW800 from Pantoea stewartii Microbiology, October 1, 2001; 147(10): 2757 - 2767. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Erdmann, M. Z. Barciszewska, M. Szymanski, A. Hochberg, N. d. Groot, and J. Barciszewski The non-coding RNAs as riboregulators Nucleic Acids Res., January 1, 2001; 29(1): 189 - 193. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||